AbbVie: acquires ImmunoGen

(CercleFinance.com) - AbbVie announces that it has completed the acquisition of ImmunoGen, whose portfolio of products complements AbbVie's existing oncology portfolio and has the potential to transform multiple solid tumors and hematological malignancies.


The transaction gives the healthcare group access to Elahere, the first and only antibody-drug conjugate approved by the US FDA for the treatment of ovarian cancer.

AbbVie confirms its FY 2024 adjusted EPS target range of $11.05-11.25, but lowers its Q1 range by 4 cents to between $2.26 and $2.30, due to the acquisition of ImmunoGen.


Copyright (c) 2024 CercleFinance.com. All rights reserved.